{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:55:47Z","timestamp":1787784947940,"version":"build-2784847793"},"reference-count":51,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK","award":["14292\/218731"],"award-info":[{"award-number":["14292\/218731"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Men who have sex with men (MSM) are at increased risk for human papillomavirus (HPV)-related anal cancer and may benefit from targeted vaccination campaigns, but it is unclear whether vaccination of sexually active MSM still prevents anal HPV infections. Protocolised data on vaccine effectiveness (VE) in routine vaccination programmes targeting MSM are limited. We describe a protocol to evaluate the VE against anal HPV-16\/18 infections in young MSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This observational study compares HPV-16\/18 infection prevalence between vaccinated and unvaccinated MSM of the same age. We recruit MSM at the Sexual Health Center of Amsterdam, born in 1996\u20132003, who receive bivalent HPV vaccination (Cervarix) (group 1). Participants complete a questionnaire on demographics and sexual behaviour and provide anal, penile, oral gargle and venous blood samples at months 0 and 24. Adverse events are monitored by a questionnaire 2 weeks post vaccine. Recruitment of group 2, also MSM born in 1996\u20132003, but not vaccinated against HPV, will start 24 months after recruitment of group 1. The same samples are collected, and the same questionnaire is administered. Anal samples are tested for HPV DNA and, if positive, typed for 25 HPV genotypes including HPV-16\/18; serum samples are tested for HPV-16\/18 antibodies; other samples are stored for future analyses. Type-specific VE will be estimated as 1\u2013OR, where OR refers to the OR of DNA positivity in group 1 at month 24 versus DNA positivity of group 2 for the respective vaccine types. Recruitment of group 1 started in February 2023 and was completed in June 2024. From February 2025 onwards, group 1 will return for the 24-month visit and recruitment of group 2 will start.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the medical ethics committee of the Amsterdam University Medical Center. This protocol presents minimal risk to participants. Findings will be presented to stakeholders in immunisation policy and be disseminated through scientific journals and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Information System 2022-502224-49-00.<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-101634","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T14:25:34Z","timestamp":1756218334000},"page":"e101634","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Human papillomavirus (HPV) vaccine effectiveness against anal HPV-16 and HPV-18 infections among young men who have sex with men visiting the sexual health center of Amsterdam (HPV4M): study protocol of an observational study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0839-9808","authenticated-orcid":false,"given":"Sarah","family":"van Veelen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Institute for Immunology & Infectious Diseases (AII), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Institute (APH), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Alberts","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Institute for Immunology & Infectious Diseases (AII), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Department of Epidemiology and Data Science, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoornenborg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Institute for Immunology & Infectious Diseases (AII), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-4261","authenticated-orcid":false,"given":"Sylvia M","family":"Bruisten","sequence":"additional","affiliation":[{"name":"Public Health Laboratory, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"Vermeij","sequence":"additional","affiliation":[{"name":"Soa Aids Netherlands, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"van der Klis","sequence":"additional","affiliation":[{"name":"Laboratory for Immunology, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luann","family":"Noordpool","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-5141","authenticated-orcid":false,"given":"Johannes A","family":"Bogaards","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Immunology & Infectious Diseases (AII), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Institute (APH), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Department of Epidemiology and Data Science, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten Franciscus","family":"Schim van der Loeff","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Institute for Immunology & Infectious Diseases (AII), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Institute (APH), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2025123106473935000_15.8.e101634.1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CEJ.0000000000000842","article-title":"Global trends in anal cancer incidence and mortality","volume":"33","author":"Mignozzi","year":"2024","journal-title":"Eur J Cancer Prev"},{"key":"2025123106473935000_15.8.e101634.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33185"},{"key":"2025123106473935000_15.8.e101634.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70080-3"},{"key":"2025123106473935000_15.8.e101634.4","unstructured":"Cancer.Net . Statistics adapted from the american cancer society\u2019s (acs) publication the acs website; the international agency for research on cancer website; and the national cancer institute\u2019s surveillance. 2023. Available: https:\/\/www.cancer.net\/cancer-types\/anal-cancer\/statistics#:~:text=If%20the%20cancer%20is%20diagnosed,survival%20rate%20is%20about%2067%25"},{"key":"2025123106473935000_15.8.e101634.5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"The Lancet"},{"key":"2025123106473935000_15.8.e101634.6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025123106473935000_15.8.e101634.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28963"},{"key":"2025123106473935000_15.8.e101634.8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00108-9"},{"key":"2025123106473935000_15.8.e101634.9","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1093\/cid\/ciac581","article-title":"Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies","volume":"76","author":"Wei","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025123106473935000_15.8.e101634.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100551","article-title":"Clearance of anal and penile HPV 6, 11, 16, and 18 DNA and antibodies among adolescent men who have sex with men (HYPER): An observational cohort study","volume":"20","author":"Tian","year":"2024","journal-title":"Vaccine X"},{"key":"2025123106473935000_15.8.e101634.11","unstructured":"European AIDS Clinical Society . European aids clinical society. 2023. Available: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines [Accessed 26 Sep 2024]."},{"key":"2025123106473935000_15.8.e101634.12","unstructured":"National Institutes of Health . Clinical guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with hiv: human papillomavirus disease. 2023. Available: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/human?view=brief [Accessed 26 Sep 2024]."},{"key":"2025123106473935000_15.8.e101634.13","unstructured":"Nederlandse vereniging van HIV behandelaren (NVHB) . Screening for anal premalignant lesions [in dutch]. 2023. Available: https:\/\/richtlijnhiv.nvhb.nl\/index.php\/Screening_anale_premaligne_afwijkingen [Accessed 26 Sep 2024]."},{"key":"2025123106473935000_15.8.e101634.14","first-page":"1","article-title":"British HIV Association guidelines for HIV-associated malignancies 2014","volume":"15 Suppl 2","author":"Bower","year":"2014","journal-title":"HIV Med"},{"key":"2025123106473935000_15.8.e101634.15","unstructured":"Ong J , McCloskey J , Tong W . HIV management guidelines: human papillomavirus infection and associated malignancies in hiv-infected people: australian society of hiv medicine (ashm). 2019. Available: https:\/\/hiv.guidelines.org.au\/management\/human-papillomavirus-infection-and-associated-malignancies-in-hiv-infected-people\/anal-cancer\/ [Accessed 26 Sep 2024]."},{"key":"2025123106473935000_15.8.e101634.16","doi-asserted-by":"publisher","DOI":"10.4161\/hv.36121"},{"key":"2025123106473935000_15.8.e101634.17","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine (Auckl)"},{"key":"2025123106473935000_15.8.e101634.18","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1548282"},{"key":"2025123106473935000_15.8.e101634.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1098-3","article-title":"Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review","volume":"16","author":"Harder","year":"2018","journal-title":"BMC Med"},{"key":"2025123106473935000_15.8.e101634.20","unstructured":"Human papillomavirus vaccines: cervarix, gardasil, gardasil 9, silgard. European Medicines Agency (EMA), 2024. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard"},{"key":"2025123106473935000_15.8.e101634.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010971"},{"key":"2025123106473935000_15.8.e101634.22","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30687-3"},{"key":"2025123106473935000_15.8.e101634.23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/infdis\/jiad005","article-title":"Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men","volume":"228","author":"Chambers","year":"2023","journal-title":"J Infect Dis"},{"key":"2025123106473935000_15.8.e101634.24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/infdis\/jiae394","article-title":"Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18-45 Years Attending Sexual Health Clinics in 3 United States Cities, 2018-2023","volume":"231","author":"DeSisto","year":"2025","journal-title":"J Infect Dis"},{"key":"2025123106473935000_15.8.e101634.25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/OLQ.0000000000001560","article-title":"Anal Human Papillomavirus Prevalence Among Vaccinated and Unvaccinated Gay, Bisexual, and Other Men Who Have Sex With Men in Canada","volume":"49","author":"Chambers","year":"2022","journal-title":"Sex Transm Dis"},{"key":"2025123106473935000_15.8.e101634.26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa306"},{"key":"2025123106473935000_15.8.e101634.27","first-page":"1280","article-title":"Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands","volume":"221","author":"Woestenberg","year":"2020","journal-title":"J Infect Dis"},{"key":"2025123106473935000_15.8.e101634.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002756","article-title":"Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach","volume":"16","author":"Bogaards","year":"2019","journal-title":"PLoS Med"},{"key":"2025123106473935000_15.8.e101634.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.12.007"},{"key":"2025123106473935000_15.8.e101634.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70471-1"},{"key":"2025123106473935000_15.8.e101634.31","unstructured":"Netherlands HCot . Change to HPV Vaccine Doses The Hague, August 30, 2022 Ed. 2022."},{"key":"2025123106473935000_15.8.e101634.32","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2016.02.019","article-title":"Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines","volume":"34","author":"Faust","year":"2016","journal-title":"Vaccine (Auckl)"},{"key":"2025123106473935000_15.8.e101634.33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pvr.2016.01.001","article-title":"High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in S\u00e3o Paulo, Brazil","volume":"2","author":"Fontes","year":"2016","journal-title":"Papillomavirus Res"},{"key":"2025123106473935000_15.8.e101634.34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit657"},{"key":"2025123106473935000_15.8.e101634.35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2025123106473935000_15.8.e101634.36","doi-asserted-by":"publisher","DOI":"10.1086\/656320"},{"key":"2025123106473935000_15.8.e101634.37","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00720-09"},{"key":"2025123106473935000_15.8.e101634.38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/QAD.0000000000000909","article-title":"The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM","volume":"30","author":"Mooij","year":"2016","journal-title":"AIDS"},{"key":"2025123106473935000_15.8.e101634.39","doi-asserted-by":"crossref","first-page":"107094","DOI":"10.1016\/j.ijid.2024.107094","article-title":"Prevalence and risk factors for HPV seropositivity and anogenital DNA positivity among men who have sex with men: a repeated cross-sectional study","volume":"145","author":"Kusters","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025123106473935000_15.8.e101634.40","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.vaccine.2020.03.002","article-title":"HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination","volume":"38","author":"Woestenberg","year":"2020","journal-title":"Vaccine (Auckl)"},{"key":"2025123106473935000_15.8.e101634.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-014-0668-z","article-title":"Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study","volume":"14","author":"van Aar","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025123106473935000_15.8.e101634.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2012.01826.x"},{"key":"2025123106473935000_15.8.e101634.43","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0298","article-title":"Capturing multiple-type interactions into practical predictors of type replacement following human papillomavirus vaccination","volume":"374","author":"Man","year":"2019","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2025123106473935000_15.8.e101634.44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix582"},{"key":"2025123106473935000_15.8.e101634.45","unstructured":"Centers for Disease Control and Prevention . HPV vaccination: recommendations of the acip. 2021. Available: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/recommendations.html [Accessed 03 Jul 2025]."},{"key":"2025123106473935000_15.8.e101634.46","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu . Tijdstip van vaccinaties (rijksvaccinatieprogramma) [in dutch]. 2025. Available: https:\/\/rijksvaccinatieprogramma.nl\/professionals\/richtlijnen\/uitvoering\/7-tijdstip-van-vaccinaties [Accessed 03 Jul 2025]."},{"key":"2025123106473935000_15.8.e101634.47","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/infdis\/jiad183","article-title":"Impact of Human Papillomavirus Vaccine Against Anal Human Papillomavirus Infection, Anal Intraepithelial Neoplasia, and Recurrence of Anal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis","volume":"228","author":"Wei","year":"2023","journal-title":"J Infect Dis"},{"key":"2025123106473935000_15.8.e101634.48","article-title":"Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study","volume":"13","author":"Yao","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"2025123106473935000_15.8.e101634.49","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-0853"},{"key":"2025123106473935000_15.8.e101634.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.06.003"},{"key":"2025123106473935000_15.8.e101634.51","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2015.08.079","article-title":"The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination","volume":"33","author":"Matthijsse","year":"2015","journal-title":"Vaccine (Auckl)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-101634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:49:53Z","timestamp":1767192593000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-101634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2025-101634"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-101634","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}